Estabrook Capital Management purchased a new position in shares of Bioverativ Inc (NASDAQ:BIVV) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 4,500 shares of the biotechnology company’s stock, valued at approximately $257,000.
A number of other institutional investors and hedge funds have also bought and sold shares of BIVV. Woodford Investment Management Ltd acquired a new stake in Bioverativ during the third quarter worth $85,455,000. Old Mutual Global Investors UK Ltd. acquired a new stake in Bioverativ during the third quarter worth $96,827,000. Bank of New York Mellon Corp acquired a new stake in Bioverativ during the third quarter worth $71,032,000. Jennison Associates LLC acquired a new stake in Bioverativ during the third quarter worth $56,420,000. Finally, Frontier Capital Management Co. LLC acquired a new stake in Bioverativ during the third quarter worth $54,653,000. Hedge funds and other institutional investors own 96.95% of the company’s stock.
Shares of Bioverativ Inc (NASDAQ BIVV) opened at $50.57 on Monday. Bioverativ Inc has a 52 week low of $40.00 and a 52 week high of $64.41.
Bioverativ (NASDAQ:BIVV) last issued its earnings results on Thursday, October 26th. The biotechnology company reported $0.80 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.55 by $0.25. Bioverativ had a net margin of 40.44% and a return on equity of 69.03%. The company had revenue of $291.60 million for the quarter, compared to the consensus estimate of $285.45 million. The company’s quarterly revenue was up 27.2% compared to the same quarter last year. research analysts forecast that Bioverativ Inc will post 2.45 earnings per share for the current fiscal year.
BIVV has been the topic of a number of recent research reports. Zacks Investment Research downgraded shares of Bioverativ from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 1st. Cowen Inc reiterated a “buy” rating and set a $80.00 price target on shares of Bioverativ in a research note on Friday, August 4th. Royal Bank Of Canada started coverage on shares of Bioverativ in a research note on Thursday, September 14th. They set a “sector perform” rating and a $59.00 price target on the stock. Evercore ISI started coverage on shares of Bioverativ in a research note on Wednesday, August 16th. They issued an “in-line” rating and a $58.00 target price on the stock. Finally, Piper Jaffray Companies restated an “overweight” rating and issued a $71.00 target price on shares of Bioverativ in a research note on Monday, October 23rd. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Bioverativ currently has an average rating of “Hold” and a consensus price target of $60.93.
ILLEGAL ACTIVITY WARNING: This news story was first reported by Transcript Daily and is owned by of Transcript Daily. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://transcriptdaily.com/2017/11/27/estabrook-capital-management-purchases-new-position-in-bioverativ-inc-bivv.html.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ Inc and related companies with MarketBeat.com's FREE daily email newsletter.